CAI · NASDAQ · STOCK
Caris Life Sciences (CAI) Stock Analysis
$29.66
52W $14.19 – $33.65
53/100
$8.40B
79.9
0.68
Is CAI Bullish or Bearish?
Mixed.
Innellis AI committee rates Caris Life Sciences, Inc. (CAI) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.91 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -13.09 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.25 across 4 articles, 14d). Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 18.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 38.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- News sentiment is positive (+0.25 across 4 articles, 14d) — News
Bear Case
- P/E of 79.8 is expensive by classic value standards — Value
- Price-to-book of 13.2x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Bollinger bandwidth of 25.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 78%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 18.8% shows genuine earnings power backing the valuation
− P/E of 79.8 is expensive by classic value standards
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 38.5% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
51
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 25.4% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 53.1 to 53.1.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
54.5
Neutral
MACD Histogram
-0.552
Bearish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Hh Hl
Support
$28.27
Resistance
$42.50
Bollinger %B
0.49
Inside Bands
Price vs Moving Averages
EMA 9
$28.91
Above
EMA 21
$28.62
Above
EMA 50
$26.09
Above
EMA 200
$23.00
Above
Fundamental Analysis
Valuation
33
Growth
40
Profitability
38
Financial Health
93
Cash Flow
70
Valuation
P/E Ratio
79.9×
P/B Ratio
14.20×
PEG Ratio
0.29
Dividend Yield
0.00%
52W High
$33.65
52W Low
$14.19
Quality & Growth
ROE
-9318.4%
ROA
-4779.0%
Gross Margin
6966.1%
Operating Margin
1548.7%
Revenue Growth YoY
—
Debt / Equity
0.76
AI Fundamental Assessment
P/E ratio of 79.9 (rich relative to a 15-40x range); Price-to-book of 14.2x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -93.2%; Return on assets of -47.8%; Net margin of 10.6%; Gross margin of 69.7%; Current ratio of 5.53 (healthy short-term liquidity); Debt-to-equity of 0.76; Free cash flow per share is positive (0.52); Most recent quarter missed estimates by 100.0%; EPS growth decelerating (+241.5% -> -100.0% QoQ); Analyst estimates falling over recent quarters
Get the Full CAI Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →